Benefits of COVID vaccine for children outweigh risks, FDA says
Food and Drug Administration regulators said Friday that the benefits of the Pfizer-BioNTech vaccine for children far outweigh the risks for children ages 5 to 11.
Why it matters: The announcement could add momentum to the FDA's authorization of doses for children on an emergency basis, which could happen as early as next week, according to the New York Times.
Driving the news: The remarks came on the same day that the FDA released data showing the Pfizer vaccine had a 90.7% efficacy rate in preventing symptomatic COVID-19 in a trial of 5- to 11-year-olds.
Regulators wrote...